Eye­ing growth in re­gen­er­a­tive med­i­cine, Fu­ji­film spends $800M on two new mem­bers of its CD­MO busi­ness

In a sign that it’s dou­bling-down on the con­tract man­u­fac­tur­ing and de­vel­op­ment busi­ness, Japan’s Fu­ji­film is pay­ing $800 mil­lion to ac­quire two com­pa­nies spe­cial­iz­ing in cell cul­ture me­dia.

Both com­pa­nies, Irvine Sci­en­tif­ic Sales Com­pa­ny (IS­US) and IS Japan (ISJ), were pre­vi­ous­ly owned by Japan­ese pe­tro­le­um gi­ant JXTG. Cell ther­a­pies, in­clud­ing CAR-T and re­gen­er­a­tive stem cell ther­a­pies, will be a key fo­cus, Fu­ji­film writes in a de­tailed state­ment map­ping out its plans.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER